EMA validates Bayer’s asundexian application for ischaemic stroke
The European Medicines Agency (EMA) has validated Bayer's marketing authorisation application for asundexian, an oral Factor XIa inhibitor, to prevent…
10 Jun 2026
Parabilis Medicines sets biotech record with $670m IPO
Parabilis Medicines has secured the largest initial public offering (IPO) in biotech history, suggesting that an uptick of upsized public listings in the sector shows no signs of slowing. Parabilis,…
10 Jun 2026
Eli Lilly continues dealmaking roll with $1bn AlzeCure agreement
Eli Lilly has inked a licensing deal worth up to $1bn with Swedish Alzheimer’s-focused biotech, AlzeCure – marking a continuation of the pharma giant’s 2026 dealmaking spree. Lilly will secure…
10 Jun 2026
Aditxt and Ignite announce merger plans with strategic partner
Health innovation platform developer Aditxt and its fully owned subsidiary Ignite Proteomics have announced their plans for a business combination with a strategic partner that values the latter at an…
10 Jun 2026
MHRA to roll out new AI sandbox for medicines development
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has announced plans to launch a new AI sandbox to expedite the development of medicines and improve safety. The programme will…
09 Jun 2026
WuXi AppTec hits back after being named in Pentagon’s Chinese military list
The Pentagon has judged that Wuxi AppTec qualifies as a Chinese military company, adding strain to already delicate ties between the pharmaceutical manufacturer and the US. The US Department of…
09 Jun 2026
GSK doubles down on oncology with $10.6bn Nuvalent takeover
GSK will acquire lung cancer biotech Nuvalent for $10.6bn in one of its largest ever deals, bolstering its pipeline with two late-stage assets the drugmaker believes have “multi-blockbuster potential”. The…